Form 4: Bionano Genomics Director Receives Stock Option Grant

Director Aleksandar Rajkovic was granted 9,149 stock options in Bionano Genomics as part of standard equity compensation.

Summary

• Director Aleksandar Rajkovic received a grant of 9,149 stock options on May 14, 2026.
• The options have an exercise price of $1.19 per share.
• The options are set to expire on May 13, 2036.
• Vesting occurs in equal monthly installments over 12 months, with full vesting guaranteed by the next annual stockholder meeting.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on the company's operational outlook.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• Dilutive impact of new option grants on existing shareholders.

Risks

• Potential for future dilution if options are exercised.
• Market price volatility affecting the value of the granted options.

Future Outlook

The options vest over 12 months or upon the next annual stockholder meeting, indicating a short-term retention and incentive structure for the director.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard practice in the biotechnology sector to attract and retain board expertise, though investors should monitor total dilution levels.

Comparison to Industry Standards

• The grant size and vesting schedule are consistent with standard corporate governance practices for small-cap biotech firms.
• The use of 12-month vesting is relatively aggressive compared to the typical 3-4 year vesting schedules seen in larger cap companies.

Corporate Governance

Stakeholder Impact

• Minor dilution for existing shareholders upon potential future exercise of options.

Next Steps

• Vesting of options over the next 12 months.
• Potential exercise of options by the director upon vesting.

Key Dates

Keywords

Bionano Genomics, BNGO, Director Compensation, Stock Options, Insider Transaction, Form 4